For years, CRISPR Therapeutics (CRSP 1.25%) has been the type of stock investors might call a home run swing. The company ...
When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with ...
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...
UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease. The trial is the first in the U.S. to apply non-viral CRISPR-Cas9 ...
UrbanGeekz on MSN
How gene therapy could end sickle cell disease
For generations, Sickle Cell Disease has been a devastating illness affecting millions of people around the world, ...
This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. For more than a year, Victoria Gray's ...
Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost. Victoria Gray, cured of sickle ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Editas Medicine said Tuesday it will ...
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending a CRISPR gene editing-based treatment for severe sickle cell disease (SCD). The regulator said ...
In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results